Department of Health and Human Services May 16, 2005 – Federal Register Recent Federal Regulation Documents
Results 1 - 12 of 12
OCS; Notice of Correction for the CCF Demonstration Program Announcement
This notice is to inform interested parties of corrections made to the CCF Demonstration Program published on Friday, April 29, 2005. The following corrections should be noted: Under IV.6 Other Submission Requirements, the correct address to mail and hand deliver applications is: U.S. Department of Health and Human Services (HHS), Attention: Eduardo Hernandez, Administration for Children and Families Office of Community Services, Operations Center, Compassion Capital Fund Demonstration Program, 1515 Wilson Boulevard, Suite 100, Arlington, Virginia 22209. Phone: 1-800-281-9519. E-mail: OCS@lcgnet.com. The only changes to the CCF Demonstration Program Announcement are explicitly stated in this Notice of Correction. All applications must still be sent on or before the deadline date of June 13, 2005. For further information contact the OCS Grants Operations Center at the above phone number or address.
Office of Community Services: Notice of Correction for the CCF Targeted Capacity Building Program Announcement
This notice is to inform interested parties of corrections made to the CCF Targeted Capacity Building Program published on Friday, April 29, 2005. The following corrections should be noted: Under IV.6 Other Submission Requirements, the correct address to mail and hand deliver applications is: U.S. Department of Health and Human Services (HHS), Attention: Eduardo Hernandez, Administration for Children and Families Office of Community Services, Operations Center, Compassion Capital Fund Targeted Capacity Building Program, 1515 Wilson Boulevard, Suite 100, Arlington, Virginia 22209, Phone: 1-800-281-9519, E-mail: OCS@lcgnet.com. The only changes to the CCF Targeted Capacity Building Program Announcement are explicitly stated in this Notice of Correction. All applications must still be sent on or before the deadline date of May 31, 2005.
Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting
National Toxicology Program (NTP); Liaison and Scientific Review Office (LSRO); Meeting of the NTP Board of Scientific Counselors
Pursuant to Public Law 92-463, notice is hereby given of a meeting of the National Toxicology Program (NTP) Board of Scientific Counselors. The NTP Board of Scientific Counselors (NTP Board) is composed of scientists from the public and private sectors and provides primary scientific oversight to the Director for the NTP and evaluates the scientific merit of the NTP's intramural and collaborative programs.
CollaGenex Pharmaceuticals, Inc.; Withdrawal of Approval of a New Drug Application; Determination That Doxycycline Hyclate 20-Milligram Capsules Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA) is withdrawing approval of one new drug application (NDA). CollaGenex Pharmaceuticals, Inc., notified the agency in writing that PERIOSTAT (doxycycline hyclate) 20- milligram (mg) capsules were no longer marketed and requested that approval of NDA 50-774 be withdrawn. FDA has determined that PERIOSTAT (doxycycline hyclate) 20-mg capsules were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for doxycycline hyclate 20-mg capsules.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
